Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant ...

Jackson, MS - New research suggests that mycophenolate mofetil (MMF) can be used in the management of autoimmune inflammatory myopathy. The finding, published in the March 2005 issue of Rheumatology, ...

Idiopathic inflammatory myopathies (IIM) represent a heterogeneous group of autoimmune disorders primarily characterised by progressive muscle weakness and inflammation, but with potential involvement ...

The new Scoring system for Cancer Risk in idiopathic Inflammatory Myositis (SCRIM), which incorporated age, sex, smoking status, dermatomyositis, anti‑transcriptional intermediary factor 1‑gamma (anti ...

Early-onset IBM challenges age-centric diagnostic criteria, with symptoms appearing in patients younger than 46. Younger IBM patients show a higher rate of mitochondrial DNA mutations, indicating ...

History gathering should solicit the patient’s abilities or limitations with these activities of daily living (ADLs). The patient may have mild arthralgias. Lungs are the most common extra muscular ...

Idiopathic inflammatory myopathies (IIMs) comprise a group of inflammatory disorders in which there is chronic inflammation of skeletal muscle. This is then followed by muscle weakness. One type of ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful ...

Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase ...

Generalized MG should be suspected when clinicians see fluctuating, fatigable weakness ...